reMYND is a clinical stage company developing treatments for Alzheimer’s, Huntington's, epilepsy and other diseases caused by cellular dysfunction. It is backed by a proprietary drug discovery platform, which enables the identification of novel mechanisms-of-action, targets and first-in-class small molecules.
reMYND’s most advanced program is ReS19-T, an investigational compound for the treatment of Alzheimer’s, ready to start Phase 2a. In animal models it has been shown to produce an acute response, restoring synaptic plasticity, a process central in the disease cascade leading to neuronal demise and build-up of plaques and tangles. Similarly, reMYND’s Huntington program fully restores cortico-striatal transmission and regenerates the mouse brain in the standard Huntington knock-in mice.
Other treatments for major health challenges are being explored using reMYND’s discovery platform, with a focus on mitochondrial dysfunction in central nervous system (CNS) disorders.
In addition, reMYND has a dedicated Contract Research Organization (CRO), which focuses on CNS disorders. The team helps clients to assess the pharmacokinetics, pharmacodynamics and efficacy of their experimental treatments in reMYND’s proprietary animal models. The CRO has a global client base, including the US, Europe and Japan.